OMNIAB, INC. Stock-Based Compensation
OMNIAB, INC. (OABI) reported Stock-Based Compensation of $6.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- OMNIAB, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.16M, a 23.16% decline year-over-year.
- OMNIAB, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.34M, a 19.40% decline year-over-year.
- OMNIAB, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.61M, a 29.52% decline year-over-year.
- OMNIAB, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.96M, a 25.30% decline year-over-year.
- OMNIAB, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $15.82M, a 26.40% decline from fiscal 2024.
- OMNIAB, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $21.50M, a 13.38% decline from fiscal 2023.
- OMNIAB, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $24.82M, a 35.47% increase from fiscal 2022.
- OMNIAB, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $18.32M, a 21.62% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.50M 10-Q · filed 2026-08-06 | $10.11M derived: sum of 3 quarters · filed 2026-08-06 | $14.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.34M 10-Q · filed 2026-05-07 | $6.95M derived: sum of 2 quarters · filed 2026-05-07 | $10.91M derived: sum of 3 quarters · filed 2026-05-07 | $15.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $7.57M derived: sum of 2 quarters · filed 2026-03-04 | $11.68M derived: sum of 3 quarters · filed 2026-08-06 | $15.82M 10-K · filed 2026-03-04 |
| 2025-09-30 | $3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $8.07M derived: sum of 2 quarters · filed 2026-08-06 | $12.22M 10-Q · filed 2025-11-04 | $17.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.26M 10-Q · filed 2026-08-06 | $13.37M derived: sum of 3 quarters · filed 2026-08-06 | $18.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.14M 10-Q · filed 2026-05-07 | $9.26M derived: sum of 2 quarters · filed 2026-05-07 | $14.56M derived: sum of 3 quarters · filed 2026-05-07 | $19.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $10.42M derived: sum of 2 quarters · filed 2026-03-04 | $15.80M derived: sum of 3 quarters · filed 2026-03-04 | $21.50M 10-K · filed 2026-03-04 |
| 2024-09-30 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $10.69M derived: sum of 2 quarters · filed 2025-11-04 | $16.38M 10-Q · filed 2025-11-04 | $22.31M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $11.08M 10-Q · filed 2025-08-06 | $17.00M derived: sum of 3 quarters · filed 2025-08-06 | $23.31M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $5.70M 10-Q · filed 2025-05-08 | $11.62M derived: sum of 2 quarters · filed 2025-05-08 | $17.93M derived: sum of 3 quarters · filed 2025-05-08 | $24.46M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $12.24M derived: sum of 2 quarters · filed 2025-03-18 | $18.77M derived: sum of 3 quarters · filed 2025-03-18 | $24.82M 10-K · filed 2025-03-18 |
| 2023-09-30 | $6.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $12.84M derived: sum of 2 quarters · filed 2024-11-12 | $18.89M 10-Q · filed 2024-11-12 | $24.94M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $6.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $12.58M 10-Q · filed 2024-08-08 | $18.63M derived: sum of 3 quarters · filed 2024-08-08 | $23.91M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $6.05M 10-Q · filed 2024-05-09 | $12.10M derived: sum of 2 quarters · filed 2024-05-09 | $17.38M derived: sum of 3 quarters · filed 2024-05-09 | $21.23M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $11.33M derived: sum of 2 quarters · filed 2024-03-25 | $15.18M derived: sum of 3 quarters · filed 2024-03-25 | $18.32M 10-K · filed 2024-03-25 |
| 2022-09-30 | $5.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $9.13M derived: sum of 2 quarters · filed 2023-11-09 | $12.27M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.99M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $3.15M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $15.06M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |